6α-Methylprednisolone and 6α-Methylprednisone Plasma Protein Binding in Humans and Rabbits

doi:10.1002/jps.2600750807

Journal of Pharmaceutical Sciences

Volume 75, Issue 8, August 1986, Pages 760-763

https://doi.org/10.1002/jps.2600750807 Get rights and content

Abstract

The binding of 6α-methylprednisolone and 6α-methylprednisone to proteins of rabbit and human plasma was studied in vitro by equilibrium dialysis. Steroid binding was determined using radiolabeled compounds and HPLC analysis methods. Both methods produced equivalent results. Plasma protein binding of 6α-methylprednisolone and 6α-methylprednisone averaged 75–82% and was independent of steroid concentration, suggestive of low affinity, nonspecific protein binding. A positive linear correlation of the log octanol-water partition coefficient with the nonspecific binding affinities of a homologous series of steroids, including 6α-methylprednisolone and 6α-methylprednisone, was demonstrated. This correlation suggests that hydrophobic binding is a major determinant of nonspecific steroid-protein interactions.

References and Notes (18)

M.L. Rocci et al.
J. Pharm. Sci.
(1981)
F.D. Boudinot et al.
J. Pharm. Sci.
(1984)
R.V. Tomlinson et al.
J. Steroid Biochem.
(1982)
U. Westphal
J. Steroid Biochem.
(1983)
G.L. Flynn
J. Pharm. Sci.
(1971)
J.R. Florini et al.
J. Biol. Chem.
(1961)
J.F. Tait et al.
F.D. Boudinot et al.
J. Steroid Biochem.
(1984)
K. Eik-Nes et al.
J. Biol. Chem.
(1954)

There are more references available in the full text version of this article.

Cited by (34)

Small volume rapid equilibrium dialysis (RED) measures effects of interstitial parameters on the protein-bound fraction of topical drugs
2023, Journal of Pharmaceutical and Biomedical Analysis
The importance of plasma protein binding in the early stages of drug development is well recognized. Free and bound drug fractions in plasma are routinely determined with well-established methods. However, for physiological fluids with a small accessible volume and low protein concentrations, such as dermal interstitial fluid (dISF) validated methods are currently missing. Due to the low protein concentration and highly dynamic processes in the dermis, protein binding data obtained from plasma samples may underestimate in-vivo efficacy. This study aimed to validate a small volume rapid equilibrium dialysis (RED) for low protein samples, as a tool to examine drug-protein binding directly in the biological fluid at the site of action. The sample volume required for RED was successfully downscaled to 50 µl and plasma protein binding values of the four model drugs were consistent with previous studies with an average recovery of 88 ± 8% which makes all tested drugs suitable for small volume RED. Inter- and intra-batch variability showed sufficient reproducibility across RED plates. Small volume RED was successfully applied to assess the effects of interstitial parameters, including the evaluation of the major binding protein and the effects of binding protein concentration, drug concentration, and pH on the protein-bound drug fraction using 2% HSA and/or diluted human plasma as a surrogate for dISF.
Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus
2019, Seminars in Arthritis and Rheumatism
Citation Excerpt :
Cortisol production and secretion are regulated by the hypothalamic–pituitary–adrenal (HPA) axis in response to the adrenocorticotropic hormone (ACTH) secretion by the pituitary gland [8] (Fig. 1). Synthetic glucocorticoids used in the treatment of cSLE include prednisone, prednisolone, hydrocortisone, and methylprednisolone (6-α methylprednisolone); the latter is chemically identical to prednisolone with the exception of a carbon group at position 6 [9]. The structure of the synthetic glucocorticoid hydrocortisone is chemically identical to that of the endogenous glucocorticoid cortisol [10].
Glucocorticoids are potent anti-inflammatory and immunosuppressant medications and remain the mainstay of systemic lupus erythematosus (SLE) therapy. The potency of a specific glucocorticoid, i.e., the dose of glucocorticoid that is required to produce a specific effect, is dependent on its pharmacokinetic (PK) and pharmacodynamic (PD) properties. In this review, we summarize the PK/PD properties of commonly used glucocorticoids in an attempt to better delineate their role in the management of children with childhood-onset SLE (cSLE). We also address glucocorticoid side effects as these play a major role when deciding on the dose, frequency, and duration of use. A better understanding of the pharmacology of glucocorticoids appears useful to achieve improved outcomes in the management of cSLE.
Determination of methylprednisolone acetate in biological fluids at gold nanoparticles modified ITO electrode
2007, Journal of Pharmaceutical and Biomedical Analysis
The electrochemical behavior of a corticosteroid methylprednisolone (MP), used for doping, has been studied at gold nanoparticles modified indium tin oxide (nanoAu/ITO) electrode. The nanoAu/ITO electrode exhibited an effective catalytic response towards its oxidation and lowered its oxidation potential by ∼127 mV when compared with bare ITO electrode. Oxidation of MP has been carried out in phosphate containing electrolyte in the pH range 2.13–10.00 and a well-defined oxidation peak was noticed. Linear concentration curves are obtained over the concentration range 0.01–1.0 μM with a detection limit of 2.68 × 10⁻⁷ M at nanoAu/ITO electrode. A diffusion coefficient of 2.36 × 10⁻⁶ cm²/s is calculated for MP using chronoamperometry. The proposed method is effectively applied to detect the concentration of MP in pharmaceutical formulations and human blood plasma and urine samples. A comparison of MP concentration determined in blood plasma and urine by the proposed method and GC/MS indicated that the results are essentially similar. It is believed that the method will be useful in determining this drug in case of doping.
Quantitative structure-pharmacokinetic/pharmacodynamic relationships
2006, Advanced Drug Delivery Reviews
Quantitative structure–activity relationships have long been considered a vital component of drug discovery and development, providing insight into the role of molecular properties in the biological activity of similar and unrelated compounds. Recognition that in vitro bioassay and/or pre-clinical activity are insufficient for anticipating which compounds are suitable leads for further development has shifted the focus toward integrated pharmacokinetic (PK) and pharmacodynamic (PD) processes. Over the last decade, considerable progress has been made in constructing empirical and mechanistic quantitative structure–PK relationships (QSPKR), as well as diverse mechanism-based pharmacodynamic models of drug effects. In this review, traditional and contemporary approaches to developing QSPKR models are discussed, along with selected examples of attempts to couple QSPKR and pharmacodynamic models to anticipate the intensity and time-course of the pharmacological effects of new or related compounds, or quantitative structure–pharmacodynamic relationships modeling. Such models are in accordance with the goals of systems biology and the ideal of designing drugs and delivery systems from first principles.
Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids
2006, Journal of Pharmaceutical and Biomedical Analysis
Plasma protein binding (PPB) methodology suitable for application in the lead optimisation of a corticosteroid series known to demonstrate non-specific binding (NSB) and poor solubility has been established. The method involved a modification to standard ultrafiltration (UF) techniques. In parallel with each experimental plasma sample, a control plasma sample was also processed by ultrafiltration. The retentate from experimental and control plasma samples were mixed back into the filtrate of the partner sample. The resulting regenerated plasma samples, one representing the experimental filtrate and one representing the experimental retentate, were then analysed by LC/MS/MS. Varying degrees of NSB were demonstrated with a number of corticosteroids, and this effect was eliminated using the modified method. Validation using a panel of established corticosteroids showed good agreement with published PPB figures. The published PPB figure for fluticasone propionate (FP) was, however, found to be an underestimate, and this was subsequently confirmed, at clinically relevant plasma concentrations, to be 99.3%. The modified method was particularly suited to lead optimisation because it provided samples in a consistent matrix compatible with standard high throughput LC/MS/MS analysis.
Corticosteroid therapy in asthma: Predictors of responsiveness
2006, Clinics in Chest Medicine

View all citing articles on Scopus

View full text

Articles6α-Methylprednisolone and 6α-Methylprednisone Plasma Protein Binding in Humans and Rabbits

Abstract

J. Pharm. Sci.

J. Pharm. Sci.

J. Steroid Biochem.

J. Steroid Biochem.

J. Pharm. Sci.

J. Biol. Chem.

J. Steroid Biochem.

J. Biol. Chem.

Articles
6α-Methylprednisolone and 6α-Methylprednisone Plasma Protein Binding in Humans and Rabbits